Sermorelin: Read the Historical Indication
AXON Research Institute • AXON Peptide affiliation
Educational draft • Scientific + legal review pending
Silent film with full on-screen captions. Conceptual illustrations, not molecular structures.

Sermorelin has a documented medical history. FDA records describe GEREF products previously approved for particular growth-hormone testing and pediatric growth-hormone deficiency indications. The products were later discontinued. In 2013, FDA determined that their withdrawal from sale was not for reasons of safety or effectiveness. That determination answers a regulatory question about those historical products. It does not demonstrate that every modern preparation is approved or clinically equivalent. Claims about adult recovery, body composition, or healthy aging still need evidence matched to the exact population and outcome. Historical approval alone cannot supply missing clinical trials for a different use.

END CARD
Research explained. Not medical advice. Sources and limitations in the accompanying transcript.

SOURCES
[1] FDA (2013): Determination that GEREF sermorelin acetate products were not withdrawn for reasons of safety or effectiveness
https://www.govinfo.gov/content/pkg/FR-2013-03-04/html/2013-04827.htm
Official FDA Federal Register notice

EVIDENCE LIMITATIONS
Not withdrawn for safety or effectiveness is not a finding of universal safety or current approval for all products.
Pediatric growth failure and diagnostic evidence cannot establish adult anti-aging benefit.
No claim of current commercial availability is made.

TOPIC INVENTORY PROVENANCE (not reused audiovisual media)
Sermorelin: Read the Historical Indication